Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging (INVADER_MRI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Peripheral artery disease (PAD) affects at least 12 million Americans annually with more than half a million patients undergoing an endovascular or surgical revascularization procedure in order to treat the disease. Unfortunately, about two-thirds of patients still have blockages in the leg arteries, even after these procedures.
Advances in Magnetic resonance imaging (MRI) offer promise for understanding the mechanism of failure through insights into vessel wall composition, remodeling, and inflammation. Restenosis has a known relationship to inflammation. Advances in micro-catheter technologies offer the ability to deliver anti-inflammatory medications such as Dexamethasone (DEX) directly to the adventitia and advances in drug delivery on balloon surfaces to deliver paclitaxel to the intima of the artery.
This study aims to investigate if patient-specific parameters affect angioplasty outcomes, if DEX has a biological effect on the vessel wall, and if this effect is through the reduction of inflammation.
In response to an FDA issued "Letter to Healthcare Providers" dated August 9, 2019 that reported the "relative risk for increased mortality at 5 years was 1.57 (95% confidence interval 1.16 - 2.13), which corresponds to a 57% relative increase in mortality in patients treated with paclitaxel-coated devices," participant enrollment in the paclitaxel drug coated balloon arm was stopped and a plain balloon angioplasty arm was added to the protocol.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Screening:
- Male or non-pregnant female ≥ 35 years of age
- Atherosclerotic, infrainguinal PAD
- Rutherford Clinical Category 2-6
- Stenosis detected by radiology that in the clinician's opinion is the reason for the PAD symptoms
- Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen
- Estimated Glomerular Filtration Rate (eGFR) ≥ 30 and/or threshold established by the local Institutional Review Board or Committee of Human Research
Procedural Criteria:
- De novo atherosclerotic lesion qualifying for angioplasty
- A patent artery proximal to the index lesion. Concomitant inflow procedures, including open femoral artery endarterectomy and/or stenting of the iliac arteries, are permissible.
- >50% diameter stenosis of the superficial femoral artery and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3 mm and ≤ 8mm
- Successful wire crossing of lesion
- Successful angioplasty of the index lesion or part of the index lesion, defined as ≤30% residual lumen stenosis compared with adjacent non-diseased lumen diameter, without flow-limiting dissection
Exclusion Criteria:
Screening Criteria:
- Any contraindication to receiving an MRI
- Pregnant, nursing, or planning on becoming pregnant in < 2yrs
- Life expectancy of < 1 yr
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months of index procedure
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR < 30
- Prior bypass surgery, stenting, atherectomy or angioplasty of the index lesion
- Inability to take required study medications
- Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, gadolinium, aspirin or Plavix
- Systemic fungal infection
- Acute limb ischemia
- Prior participation of the index limb in the current study (contralateral treatment is allowed)
- Patient is being treated with long-term steroids (not including treatment of a bronchial condition with inhaled steroids)
Procedural Criteria:
- Index lesions extending into the tibial trifurcation or above the profunda. Note: the outflow tibial artery can be treated concomitantly. Similarly, the common femoral artery can be treated concomitantly, either with open endarterectomy and patch angioplasty or with endovascular methods. However, the index lesion cannot be contiguous with either the common femoral artery or the tibial trifurcation.
- Circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion catheter needle through the vessel wall
- Inadequate distal outflow defined as no patent tibial arteries (>50% stenosis). The outflow vessel can be established at the time of primary treatment
- Use of adjunctive therapies other than angioplasty. Chocolate balloons and/or scoring balloons are allowed, if used below reference diameter.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dexamethasone
Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
|
Participants will receive dexamethasone infusion following plain balloon angioplasty
Other Names:
|
|
Active Comparator: Drug Coated Balloon
Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA).
They will receive additional angioplasty with a paclitaxel coated balloon.
|
Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
|
|
Active Comparator: Plain Balloon Angioplasty
Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only.
They will not receive a dexamethasone infusion to the adventitia or paclitaxel.
|
Participants will receive plain balloon angioplasty only
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Percent Wall Volume (PWV)
Time Frame: From Post-Operative Day One to 12 Months
|
The change in percent wall volume (PWV) of the treated segment between the postoperative and 12 month time points as measured by MRI
|
From Post-Operative Day One to 12 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Wall Volume (WV) Without a Change in Total Vessel Volume (TVV)
Time Frame: From Post-Operative Day One to 12 Months
|
The change in wall volume (WV) without change in total vessel volume (TVV) of the treated segment between the postoperative and 12 month time points as measured by MRI
|
From Post-Operative Day One to 12 Months
|
|
Change in Perioperative Inflammatory Profile (MCP-1)
Time Frame: From Post-Operative Day One to 12 Months
|
The serum concentration of monocyte chemoattractant protein-1 (MCP-1) between postprocedure day 1 and 12 months postprocedure.
Reported as the area under the curve (AUC) of the MCP-1 concentration (postprocedure day 1, 1 month and 12 months)
|
From Post-Operative Day One to 12 Months
|
|
Change in Perioperative Inflammatory Profile (CRP)
Time Frame: From Post-Operative Day One to 12 Months
|
The serum concentration of C-reactive protein (CRP) between postprocedure day 1 and 12 months postprocedure.
Reported as the area under the curve (AUC) of the CRP concentration (postprocedure day 1, 1 month and 12 months).
|
From Post-Operative Day One to 12 Months
|
|
Change in Perioperative Inflammatory Profile (IL-1beta)
Time Frame: From Post-Operative Day One to 12 Months
|
The serum concentration of interleukin-1beta (IL-1beta) between postprocedure day 1 and 12 months postprocedure.
Reported as the area under the curve (AUC) of the IL-1beta concentration (postprocedure day 1, 1 month and 12 months).
|
From Post-Operative Day One to 12 Months
|
|
Change in Transfer Constant (Ktrans)
Time Frame: From 1 Month to 6 Months
|
The change in adventitial transfer constant (Ktrans) of the treated segment between the postoperative and 6 month time points as measured by dynamic contrast enhanced MRI
|
From 1 Month to 6 Months
|
|
Change in Lumen Volume (LV) Relative to Total Vessel Volume (TVV)
Time Frame: From Post-Operative Day One to 12 Months
|
The change in lumen volume (LV) relative to total vessel volume (TVV) of the treated segment between the postoperative and 12 month time points as measured by MRI
|
From Post-Operative Day One to 12 Months
|
|
Percentage of Subjects With Clinically Significant Restenosis That Undergo Reintervention of Greater Than or Equal to 75% of the Treated Segment
Time Frame: From Post-Operative Day One to 12 Months
|
Percentage of subjects with clinically significant restenosis that undergo reintervention of greater than or equal to 75% of the treated segment by the 12 month timepoint.
|
From Post-Operative Day One to 12 Months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Extended Clinical Adverse Events Monitoring
Time Frame: From Post-Operative Day One to 36 Months
|
Participant monitoring for clinical adverse events
|
From Post-Operative Day One to 36 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Warren Gasper, MD, San Francisco VA Medical Center
- Principal Investigator: David Saloner, PhD, San Francisco VA Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Atherosclerosis
- Arteriosclerosis
- Arterial Occlusive Diseases
- Peripheral Vascular Diseases
- Ischemia
- Chronic Limb-Threatening Ischemia
- Vascular Diseases
- Peripheral Arterial Disease
- Antineoplastic Agents
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
Other Study ID Numbers
- 15-17251
- 1R01HL128816-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
NCT06052319CompletedCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)
-
NCT06389149RecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive Disease
-
NCT00380016CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery Disease
-
NCT06951685RecruitingPeripheral Artery Occlusive Disease
-
NCT05941533RecruitingPeripheral Artery Disease (PAD)
-
NCT05665816Not yet recruiting
-
NCT04821388Active, not recruitingPeripheral Artery Disease (PAD)
-
NCT07000097Active, not recruiting
-
NCT03744572CompletedPeripheral Artery Disease (PAD)
-
NCT03023098CompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery Restenosis
Clinical Trials on Dexamethasone infusion
-
NCT04856631RecruitingHead and Neck Squamous Cell Cancer
-
NCT02525432Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, Acute
-
NCT00813267UnknownOsteochondritis of the Femoral Head
-
NCT07363109Not yet recruitingHypotension After Spinal Anesthesia | Hypotension During Cesarean Delivery
-
NCT04938934Completed
-
NCT07352124CompletedHypertension With Hypertriglyceridemia
-
NCT03657537CompletedCognitive Change | Type2 Diabetes | Ketonemia
-
NCT00248040CompletedKidney Diseases | Ischemia-Reperfusion Injury
-
NCT04826120CompletedEpidural; Analgesia
-
NCT01866358CompletedAsphyxia Neonatorum